Par Drug Patent Portfolio
Par owns 1 orange book drug protected by 1 US patent Given below is the list of Par's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7553863 | Ultrapure 4-methylpyrazole | 30 Jun, 2027 | Active |
Latest Legal Activities on Par's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Par.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Sep, 2020 | US7553863 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Jun, 2017 | US7553863 |
| Post Issue Communication - Certificate of Correction | 14 Sep, 2009 | US7553863 |
|
Recordation of Patent Grant Mailed
Critical
| 30 Jun, 2009 | US7553863 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 30 Jun, 2009 | US7553863 |
|
Email Notification
Critical
| 12 Jun, 2009 | US7553863 |
|
Issue Notification Mailed
Critical
| 10 Jun, 2009 | US7553863 |
| Dispatch to FDC | 28 May, 2009 | US7553863 |
|
Application Is Considered Ready for Issue
Critical
| 27 May, 2009 | US7553863 |
|
Issue Fee Payment Received
Critical
| 26 May, 2009 | US7553863 |
|
Issue Fee Payment Verified
Critical
| 26 May, 2009 | US7553863 |
|
Mail Notice of Allowance
Critical
| 24 Feb, 2009 | US7553863 |
|
Case Docketed to Examiner in GAU
Critical
| 18 Feb, 2009 | US7553863 |
|
Notice of Allowance Data Verification Completed
Critical
| 18 Feb, 2009 | US7553863 |
| Date Forwarded to Examiner | 20 Nov, 2008 | US7553863 |
Par's Family Patents
Recent FDA approvals and tentative approvals for Par
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Lurasidone Hydrochloride |
SUPPL-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 19 May, 2017 |
| Fingolimod |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 22 Mar, 2017 |
| Citric Acid; Magnesium Oxide; Sodium Picosulfate |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 21 Nov, 2016 |
Clinical Trials
Recent Clinical Trials by Par:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury | Swiss Paraplegic Research, Nottwil | NA |
WITHDRAWN
(Jan, 2019)
| PHASE4 |
| Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban | Assistance Publique - Hôpitaux de Paris | NA |
COMPLETED
(Mar, 2011)
| PHASE2, PHASE3 |
| Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation | Assistance Publique - Hôpitaux de Paris | Agence de La Biomédecine |
COMPLETED
(Jul, 2009)
| PHASE2 |
Par Drug List
Given below is the complete list of Par's drugs and the patents protecting them.
1. Antizol
Antizol is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7553863 | Ultrapure 4-methylpyrazole |
30 Jun, 2027
(1 year, 5 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Antizol's drug page